Iovance Biotherapeutics Inc Aktie News

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Iovance (IOVA) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in  Iovance between May 9, 2024 and May 8, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

SAN CARLOS, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on September 18, 2025 (the “Date of Grant”), the Company approved the grant of in...

Last year, Iovance Biotherapeutics (IOVA -1.59%), a small-cap biotech, made a major breakthrough. The company earned approval for Amtagvi, which became the first medicine of its kind to receive regulatory approval for advanced melanoma.

SAN CARLOS, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences:

For a roller-coaster stock, look no further than Iovance Biotherapeutics (IOVA -1.22%).

Monday won't go down as a particularly memorable trading session on the stock market. It also won't be marked as a great day for shareholders of biotech Iovance Biotherapeutics (IOVA -5.95%).

There's at least one good thing to say about Iovance Biotherapeutics (IOVA 5.71%), a small-cap biotech. The drugmaker is an innovative company.

SAN CARLOS, Calif., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on August 21, 2025 (the “Date of Grant”), the Company approved the grant of induce...